Viracta Therapeutics Inc (VIRX)

OTC Markets
Currency in USD
0.0110
-0.0041(0.00%)
Closed
VIRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
0.01020.0150
52 wk Range
0.01011.3100
Key Statistics
Edit
Prev. Close
0.1515
Open
0.0116
Day's Range
0.0102-0.015
52 wk Range
0.0101-1.31
Volume
1.5M
Average Volume (3m)
2.59M
1-Year Change
-98.23%
Book Value / Share
-0.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VIRX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Viracta Therapeutics Inc SWOT Analysis


Pipeline Pivot
Viracta narrows focus to Nana-val for EBV+ lymphomas, pausing solid tumor program to streamline development and regulatory pathways
Regulatory Clarity
FDA discussions yield potential accelerated approval filing for Nana-val in 2026, offering a clearer path to market for Viracta's lead candidate
Financial Challenges
With $30M cash reserves and a reduced workforce, Viracta faces financial hurdles while aiming to extend runway for key clinical milestones
Market Positioning
Explore Viracta's strategy to dominate the EBV+ lymphoma niche, balancing specialized focus against broader market opportunities
Read full SWOT analysis

Compare VIRX to Peers and Sector

Metrics to compare
VIRX
Peers
Sector
Relationship
P/E Ratio
0.0x−3.2x−0.6x
PEG Ratio
0.00−0.010.00
Price/Book
−0.1x0.5x2.6x
Price / LTM Sales
-12.3x3.1x
Upside (Analyst Target)
-261.9%47.1%
Fair Value Upside
Unlock17.2%8.1%Unlock

Earnings

Latest Release
Nov 13, 2024
EPS / Forecast
-0.27 / -0.27
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Viracta Therapeutics (VIRX) Stock Price Today?

The Viracta Therapeutics stock price today is 0.011.

What Stock Exchange Does Viracta Therapeutics Trade On?

Viracta Therapeutics is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Viracta Therapeutics?

The stock symbol for Viracta Therapeutics is "VIRX."

What Is the Viracta Therapeutics Market Cap?

As of today, Viracta Therapeutics market cap is 437.19K.

What is Viracta Therapeutics Earnings Per Share?

The Viracta Therapeutics EPS is -1.10.

What Is the Next Viracta Therapeutics Earnings Date?

Viracta Therapeutics will release its next earnings report on 17 Mar 2025.

From a Technical Analysis Perspective, Is VIRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.